Chiasma, a late-stage biotech developing an oral drug candidate for acromegaly, announced terms for its IPO on Monday.
The Newton, MA-based company plans to raise $75 million by offering 5.36 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chiasma would command a fully diluted market value of $375 million.
Chiasma, which was founded in 2001, plans to list on the NASDAQ under the symbol CHMA. Barclays and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of July 13, 2015.
